A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Trial Profile

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DYNAMO
  • Sponsors Infinity Pharmaceuticals; Verastem Oncology
  • Most Recent Events

    • 17 Jun 2018 Results from DUO and DYNAMO studies presented at the 23rd Congress of the European Haematology Association
    • 16 Jun 2018 Results presented in the Verastem Oncology media release.
    • 16 Jun 2018 According to a Verastem Oncology media release, data from this trial was presented at the 23rd Congress of the European Hematology Association (EHA) (June 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top